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It has been postulated that inactivation of products of both p53and
retinoblastoma susceptibility (Rb) genes by binding with E6 and
E7 proteins of oncogenic human papillomaviruses (HPVs),
respectively, may be possible pathogenic factors in the develop-
ment of cervical carcinoma (Munger et al, 1989; Scheffner et al,
1990; Werness et al, 1990; Huibregtse et al, 1991). However, the
mutation frequency of these genes in this malignancy is much
lower than other malignancies (Choo and Chong, 1993). Besides,
based on the clinical evidence, HPV infection alone may be
unlikely to explain the mechanism of malignant transformation of
cervical epithelial cells.
Abnormal transcripts of the fragile histidine triad (FHIT) gene
located at 3p14.2 have been identified in a variety of human carci-
nomas (Mao et al, 1996; Ohta et al, 1996; Sozzi et al, 1996; Fong
et al, 1997; Gemma et al, 1997; Larson et al, 1997). The 3p14.2
lies within the short arm of chromosome 3 (3p13—21.1), where
allelic deletions have been frequently observed in cervical carci-
noma (Wilke et al, 1996; Larson et al, 1997; Wistuba et al, 1997).
Integration of HPV DNA has been identified at a fragile site
(FRA3B) within the FHITlocus in cervical cancer (Wilke et al,
1996). A recent study showed that alterations of the FHITgene
expression were more frequently found in cervical cancer cell
lines compared with ovarian and endometrial cancer cell lines
(Hendricks et al, 1997). In connection with this finding, the aber-
rant FHITtranscripts were found in 17 of 25 (68%) primary
cervical carcinomas (Greenspan et al, 1997). Furthermore, loss
of heterozygosity of the locus containing the FHITgene was
frequently found in cervical intraepithelial neoplasias (CINs) adja-
cent to invasive cervical carcinomas (Wistuba et al, 1997).
To investigate a possible involvement of the aberrant expression
of the FHITgene in the carcinogenesis of cervical carcinoma, we
examined the FHITgene expression by the reverse transcriptase
polymerase chain reaction (RT-PCR) and cDNA sequence
methods in cervical carcinomas with different stages, and its
precursor lesions (low-grade and high-grade CINs) as well. We
also looked at the relation between the occurrence of the aberrant
FHITgene expression and the presence of HPV and its type.
MATERIALS AND METHODS
Tissues samples
The tissue specimens were obtained from 32 cervical carcinoma
and 18 CIN patients who were treated at the University of Tokyo
Hospital. Fresh biopsied specimens of cervical neoplastic tissue
before surgery or radiotherapy were obtained from patients who
gave informed consent to use them for research purposes.
Corresponding control tissue samples of the cervix and the vagina
were obtained only from the women who gave informed consent
(35 out of 50 cases). The biopsied tissue samples were snap frozen
in liquid nitrogen or frozen at —80°C immediately after excision.
Cryostat sections were cut for haematoxylin and eosin staining to
confirm the spread of the lesion in cancer or CIN tissue samples,
and non-neoplastic tissues were trimmed off from the frozen
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Correspondence to: H Yoshikawatissues. Tissues in which neoplastic cells comprised more than
70% of total cells were used for RNA and DNA extraction.
Regarding control tissue samples, the tissues over 70% of which
were made up of epithelial cells were used for RNA extraction by
trimming of stromal tissue. Clinical information was obtained by
chart review. Of the 32 invasive carcinoma patients, 25 had squa-
mous cell carcinoma (SSC), six had adenocarcinoma (AC) and one
had adenosquamous carcinoma (ASC). Of the 18 patients with
CIN, four had low-grade CIN (CIN 1) and 14 had high-grade CIN
(CIN 2 or 3). The average age of invasive carcinoma cases was 52
years with a range from 26 to 82 years, and that of CIN cases was
41 years with a range from 19 to 78 years. Staging of invasive
carcinoma cases, based on the International Federation of
Gynecology and Obstetrics (FIGO) criteria was as follows: 15,
stage I; eight, stage II; six, stage III; and three, stage IV (Table 1).
RNA isolation and reverse transcription (RT)
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Chatsworth, CA, USA). The mRNA was isolated from the total
RNA by the Oligotex-dT Super(TaKaRa Biomedicals, Japan).
Reverse transcription was performed in a 10-ml volume of stan-
dard buffer (Gibco, Gaithersburg, MD, USA), 500mMdNTPs, 200
mMoligo(dT) primer, 20U of Human Placenta RNasin, and 200U
of M-MLV Reverse Transcriptase (Gibco). The mRNA preheated
at 65°C for 5min was used for RT reaction at 37°C for 60min, and
the reaction was stopped by inactivating the enzyme at 95°C
for 3min.
RT PCR and cDNA sequencing method
We used the nested PCR method reported by Ohta et al, 1996) to
analyse the FHITgene expression. The first PCR was performed
in a volume of 25ml containing 0.8mMof primers of 5U2(5¢-
ATCCTGGAAGCTTTGAAGCTCA-3¢) and 3D2(5¢-TCACTG-
GTTGAATACAGGA-3¢), 50mMof each dNTP, 1 ´PCR buffer,
and 1U of the Ampli TaqGold (Perkin-Elmer Applied
Biosystems). The PCR reaction was performed for 25 cycles as
reported by Ohta et al (1996) in a Perkin-Elmer thermal cycler
(model 2400), with the exception that the hot start (95°C for
7min) was added before the thermal cycling. One microlitre of
20-fold-diluted amplified product was subjected to a second PCR
amplification with nested primers 5U1 (5¢-TCCGTAGTGCTATC-
TACATC-3¢) and 3D1 (5¢-CATGCTGATTCAGTTCCTCTTGG-
3¢) for 30 cycles. To analyse the FHITgene expression with
accuracy, we used different sets of primers MUR5 and RP2
(Hendricks et al, 1997). The PCR products were electrophoresed
on 2% agarose gels (NuSieve, FMC Bioproducts, Rockland, ME,
USA). Bands were cut from agarose gels, and DNA was extracted
using the Suprec-01 (TaKaRa). DNA was sequenced directly using
primers 5U1 and 3D1, by the TaqDyeDeoxy terminator cycle
sequencing reaction for sequence analysis on the Applied
Biosystems model 373A.
Detection and typing of HPV
The PCR for the L1 region was carried out by using the consensus
L1 primers L1C1 (5¢-CGTAAACGTTTTCCCTATTTTTTT-3¢)
(1mM), L1C2 (5¢-TACCCTAAATACTCTGTATTG-3¢) (0.5mM),
and L1C2M (5¢-TACCCTAAATACCCTATATTG-3¢) (0.5mM) for
the PCR. Other conditions of PCR were as described elsewhere
(Yoshikawa et al, 1991). Briefly, the PCR protocol was 40 cycles,
and each cycle consisted of 1.5min denaturation (95°C), 1.5min
annealing (48°C) and 2min extension (70°C). One-tenth of the
reaction was electrophoresed on a 4% agarose gel and stained with
ethidium bromide. HPV types were identified on the basis of the
restriction fragment length polymorphisms (RFLP). The PCR-
based assay (L1-PCR) can type at least 26 registered genital HPVs
such as type 6, 11, 16, 18, 30, 31, 33, 34, 35, 39, 42, 43, 44, 45, 51,
52, 53, 54, 55, 56, 58, 59, 61, 66, 68 and 70 (Yoshikawa et al,
1991). This PCR system can detect 0.01pg of HPV DNA for all
these types except for HPV DNA of types 34, 42 and 55, of which
0.1mg DNA is minimally needed for detection. We used b-actin
gene amplification to rule out false-negative results.
Statistical analysis
The statistical correlation between the FHITgene expression and
clinical characteristics were analysed by the c2 method, global c2
test and the Fisher exact test. The correlation between the FHIT
gene expression and age of the patient were analysed by the
ANOVA approach. All statistical analyses were carried out with
StatView 4.11, with statistical significance set at 5%.
RESULTS
Alteration of the FHIT gene expression in invasive
cervical carcinomas
All the 32 cervical carcinomas had detectable transcripts of
expected and/or an aberrant size of the FHITgene in the RT-PCR
assays. Each aberrant FHITband was observed reproducibly by at
least two different RT-PCR analyses. In all the corresponding
normal cervical or vaginal tissue samples, only the FHITtranscript
with expected size was identified. Aberrant transcripts of the FHIT
gene were detected in 11 out of 32 (34%) carcinomas. Among
these 11 carcinomas, three had only one band of the aberrantly
truncated FHITtranscript without the transcript of expected size
(Figure 1). The remaining eight carcinomas had the transcript of
expected size in addition to the aberrantly truncated FHITtran-
scripts (Figure 1). Sequence analysis of the aberrant FHITcDNA
revealed that all the 11 carcinomas had, at least, a deletion of exon
5—7 in common (a deletion of exon 4—7 in five, exon 5—7 in five,
and exon 4—8 in one, Figure 2). One out of the five cases which
lacked exon 5—7 had also an insertion of a 36-bp sequence
between exons 4 and 8 (Figure 2). Two cases which had the aber-
rant transcripts with a deletion of exon 4—7 showed a T to C silent
mutation at nt 294 (Figure 2). All of the FHITcDNA of expected
size detected in the eight cases contained the transcript of wt
sequence (707bp) and/or the alternatively spliced transcript with
11bp deletion (nt 812—822) in exon 10 (696bp, termed FHITb;
Mao et al, 1996).
Alteration of the FHIT gene expression in CINs
We examined the aberrant FHITgene expression in 18 CIN
tissues. The aberrant FHITtranscript was not found in four cases
with low-grade CIN (CIN1), whereas it was identified in 5 of the
14 cases with high-grade CIN (CIN2 or 3, Figure 1); a deletion of
exon 4—7 in one, a deletion of exon 4—8 in two, a deletion of exon
4 in one, and a deletion of exon 5—7 and exon 4—8 in one (Figure
2). All of the high-grade CINs had the transcripts of the expected
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Table 1 The FHIT gene expression, HPV type, and clinical data
CIN
No. Age CIN grade HPV type FHIT gene expression
Normal control Tumour tissue
1 78 CIN 1 16 Na N
2 19 CIN 1 56 N
3 22 CIN 1 58 N
4 21 CIN 1 59 N N
5 32 CIN 2 16 N N and Abb (Del. cexon 5–7, 4–8)
6 40 CIN 2 33 N
7 43 CIN 2 52 N N and Ab (Del. exon 4)
8 32 CIN 3 16 N N and Ab (Del. exon 4–8)
9 34 CIN 3 16 N
10 40 CIN 3 16 N N
11 45 CIN 3 16 N
12 46 CIN 3 16 N N
13 56 CIN 3 16 N
14 43 CIN 3 31 N N and Ab (Del. exon 4–7)
15 66 CIN 3 35 N N
16 26 CIN 3 51 N N
17 53 CIN 3 52 N N and Ab (Del. exon 4–8)
18 33 CIN 3 58 N N
Invasive carcinoma
No. Age Histology Stage HPV type FHIT gene expression
Normal control Tumour tissue
1 46 SCC Ia 52 N N and Ab (Del. exon 4–7, Nt.d
294 T®C)
2 26 SCCe Ib 16 N Ab (Del. exon 5–7)
33 3A C f Ib 16 N N
4 54 SCC Ib 16 N N and Ab (Del. exon 4–7)
5 58 SCC Ib 16 N N and Ab (Del. exon 4–8)
67 5A C I b 1 6 N
7 29 SCC Ib 18 N N and Ab (Del. exon 4–7)
8 32 SCC Ib 18 N N
9 41 ASCg Ib 18 N
10 43 SCC Ib 18 N N and Ab (Del. exon 5–7,
insertion 36 bp)
11 50 SCC Ib 18 N N
12 65 SCC Ib 18 N
13 36 AC Ib Negative N N
14 47 SCC Ib Negative N Ab (Del. exon 5–7)
15 65 SCC Ib Negative N N and Ab (Del. exon 5–7)
16 52 AC IIa 16 N
17 39 SCC IIb 16 N N
18 47 SCC IIb 16 N N
19 64 SCC IIb 16 N N
20 39 SCC IIb 18 N
21 82 SCC IIb 31 N N and Ab (Del. exon 4–7, Nt.
294 T ® C)
22 57 SCC IIb 35 N
23 39 SCC IIb 58 N N
24 35 SCC IIIb 16 N Ab (Del. exon 5–7)
25 45 SCC IIIb 16 N N
26 51 SCC IIIb 31 N N and Ab (Del. exon 4–7)
27 68 SCC IIIb 31 N
28 69 SCC IIIb 33 N N
29 69 AC IIIb 52 N N
30 79 SCC IVa 16 N N
31 61 AC IVa Negative N
32 64 SCC IVa Negative N
aN, normal; bAb, aberrant; cDel, deletion; dNt, nucleotide; eSCC, squamous cell carcinoma; fAC, adenocarcinoma;
gASC, adenosquamous carcinoma.size in addition to the aberrant transcripts. Like invasive carci-
nomas, the transcripts of the expected size had the transcript of wt
sequence (707 bp) and/or the alternatively spliced transcript with
11 bp deletion (nt 812—822) in exon 10 (696 bp).
The presence of HPV and its type in invasive cervical
carcinomas and CINs
HPV DNA was detected in 27 out of 32 invasive cervical carci-
nomas and 18 out of 18 in CINs. The type of HPV in 32 invasive
carcinomas was as follows: type 16 in 12; type 18 in seven; type
31 in three; type 33 in one; type 35 in one; type 52 in two; type 58
in one; and HPV negative in five cases. Type of HPV in the CINs
was as follows: type 16 in eight; type 31 in one; type 33 in one;
type 35 in one; type 51 in one; type 52 in two; type 56 in one; type
58 in two; and type 59 in one case. All HPV types detected in this
study were cervical cancer-associated HPV, which were subdi-
vided into high-risk HPV (types 16 and 18) and intermediate-risk
HPV (the other types). The presence of HPV and its type in each
invasive carcinoma and CIN are shown in Table 1. We examined
the incidence of the aberrant FHIT gene expression in relation to
the HPV type. In invasive carcinomas, the incidence of aberrant
FHIT gene was 33% (4 out of 12) in HPV-16-positive cases, 29%
(two out of seven) in HPV-18-positive cases, 38% (three out of
eight) in HPV other than HPV-16- and HPV-18-positive cases and
40% (two out of five) in HPV-negative cases. In CINs, the inci-
dence was 25% (two out of eight) in HPV-16-positive cases and
30% (three out of ten) in HPV other than HPV-16- and HPV-18-
positive cases. There was no significant relation between the inci-
dence of the aberrant FHIT gene expression and HPV type in both
invasive carcinomas and CINs.
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Figure 1 Aberrant transcripts of the FHIT gene in cervical invasive
carcinomas and CINs. MW, f´174-HaeIII fragment. Lanes 1–5, RT-PCR
analysis of cervical invasive carcinomas (lanes 1 and 2, aberrant transcript
only; lanes 3–5, aberrant and normal transcripts). Lanes 6 and 7, RT-PCR
analysis of high-grade CINs (aberrant and normal transcripts). Lane 8, RT-
PCR analysis of normal cervical tissue (normal transcript). Arrowhead
indicates the normal-sized (707 bp) transcript
CAGTCTTCTGAAAGCACGT TCACGT
AG AG AAAG AA  CACGT TCACGTC CA  G T T T
C
30 40 50
110 12 130
Exon 4 Exon 8
Exon 3 Exon 8
A B
C
E Exon 4 Exon 8
GTCTTCTGA AAG GTGAATTTTCAGG AATATTGGAAGTCCCAG T TG G AGCACGTTCACG T
110 120 130 140 150 160
36 bp insertion
Exon 3 Exon 9
AG AGA AAGA ACTCCA G A A AC
40 50
D Exon 3 Exon 5
AG AG AAAG A A ACTTC AAC T
40 50
Figure 2 Sequence analysis of the aberrant FHIT transcripts of cervical invasive carcinomas (A, B, C and E) and high-grade CIN (D)Relation of the aberrant FHIT gene expression with
clinical characteristics in invasive cervical carcinomas
We analysed the relation of the aberrant FHIT gene expression
with clinical characteristics such as histology, age at diagnosis and
clinical stage (Table 1).
The aberrant FHIT gene expression was detected more
frequently in invasive squamous cell carcinomas than in invasive
non-squamous carcinomas [44% (11 out of 25) vs 0% (zero out of
seven), P = 0.03, Fisher exact test].
The mean age of the patients with the aberrant FHIT gene
expression (49 years) was slightly younger than that of the patients
with normal FHIT gene expression (54 years), though the differ-
ence was not significant (P = 0.40).
We compared the incidence of the aberrant FHIT gene expression
according to clinical stage of invasive carcinoma. The incidence of
the aberrant FHIT gene expression in each stage was as follows:
53% (8 out of 15) in stage I; 13% (one out of eight) in stage II; 33%
(two out of six) in stage III; and 0% (zero out of three) in stage IV.
Although a statistically higher incidence of the aberrant FHIT gene
expression was noticed in stage I cases (P = 0.01, Fisher exact 2´2
analysis) compared with that in stage II or more advanced (stage
II—IV), there is no noticeable relation between the incidence and
clinical stage by global c2 test (P = 0.13), suggesting that there was
no tendency of an increase in the incidence of the aberrant FHIT
gene expression with advance of clinical stage.
DISCUSSION
It is still open as to whether the aberrant FHIT gene expression
occurs before development of invasive cervical carcinoma. If this
is the case, the aberrant expression of the gene may play an impor-
tant role in the carcinogenesis of cervical cancer. Here, we found
the aberrant FHIT transcripts in 5 out of 14 (35.7%) women with
high-grade CIN, a putative precursor lesion of invasive cervical
carcinoma of squamous cell type. The alteration pattern of the
aberrant transcript in high-grade CINs was essentially similar to
that in invasive carcinomas, with the exception of one CIN case
which had a deletion of exon 4.
A recent report (Wistuba et al, 1997) showed a frequent occur-
rence is a deletion of chromosome 3p containing the FHIT locus in
high-grade CINs adjacent to invasive carcinomas. In the present
study, frequent alteration of FHIT gene expression was observed
in isolated high-grade CIN unassociated with invasive lesion.
Additionally, the incidence of the alteration did not increase with
the advance of clinical stage of carcinomas (Table 1). These data
suggest that the alteration of the FHIT gene may be an early
genetic event during the generation of cervical carcinoma, but not
the consequence of cancer progression.
The RT-PCR and cDNA sequencing revealed that deletions of the
FHIT gene were more frequent than a point mutation or rearrange-
ment in invasive cervical carcinoma and CIN. In this study, the
exons 5—7 were invariably deleted with or without loss of exon 4
and/or 8 in the aberrant transcripts of the FHIT gene detected. These
results are consistent with those found in other various carcinomas
(Mao et al, 1996; Ohta et al, 1996; Sozzi et al, 1996; Fong et al,
1997; Gemma et al, 1997; Larson et al, 1997) and in cervical carci-
noma cell lines (Greenspan et al, 1997; Hendricks et al, 1997).
However, this report is first to analyse precisely the deletion of the
FHIT cDNA in primary cervical carcinoma. Considering the fact
that the predicted translation initiation codon resides in exon 5, the
aberrant FHIT transcript may fail to generate any protein product. In
8 of 11 invasive carcinomas with aberrant FHIT transcript, the
normal-sized transcript was detected as well. The coexistence of the
aberrant  FHIT transcript and the normal-sized transcript is in
keeping with previous reports which investigated various types of
cancer cell lines and primary carcinomas (Mao et al, 1996; Ohta et
al, 1996; Sozzi et al, 1996; Fong et al, 1997; Gemma et al, 1997;
Larson et al, 1997). Though we used the tissue specimens in which
neoplastic cells constituted more than 70% of the total cells for RNA
extraction, it is impossible to exclude any normal stromal cells and
lymphocytes from primary tissue specimens. Thus, a possibility that
the normal-sized transcript is derived not from neoplastic cells but
from contaminating normal cells cannot be discounted.
Several studies indicated an inverse relationship between p53
mutation and HPV positivity in cervical carcinomas (Crook et al,
1991; Crook and Vousden, 1992). It was further shown that p53
mutations were confined to the HPV-negative cell lines derived
from cervical carcinomas, although recent studies have questioned
the relation between p53 and HPV (Fujita et al, 1992; Choo and
Chong, 1993; Helland et al, 1993; Miwa et al, 1995). Regarding a
link between HPV and the FHIT gene, integration of HPV DNA
has been identified at a fragile region (FRA3B) within the FHIT
gene in cervical carcinoma (Wilke et al, 1995). However, in view of
the present result showing that there seems to be no association of
the incidence of the aberrant FHIT gene expression with the pres-
ence of HPV or its type in both invasive carcinoma and CIN, the
aberrant FHIT gene expression could participate in the carcinogen-
esis presumably in a manner unrelated to HPV infection.
The incidence of the aberrant FHIT gene expression varies
according to histopathological subtypes in certain tumours. For
instance, small-cell lung cancers show more frequent alteration of
the FHIT gene expression than other types of lung cancer (Sozzi et
al, 1996). In this study, the aberrant FHIT transcripts were detected
only in cervical invasive carcinomas with squamous cell type. It
was reported that the alteration of the FHIT gene expression was
more frequent in cervical cancer cell lines (five out of eight)
compared with cell lines derived from ovarian (2 out of 14) or
endometrial carcinomas (zero out of four), which are predomi-
nantly adenocarcinoma (Hendricks et al, 1997). Taken together,
these data suggest that FHIT alterations may be more closely
related to carcinogenesis of squamous cell carcinoma than to that
of adenocarcinoma in gynaecological malignancies.
In conclusion, we demonstrated that the aberrant expression of the
FHIT gene was found in CIN as well as invasive cervical carcinoma,
with its incidence being unchanged during progressional process.
Given the squamous cell carcinoma dominant occurrence, the aber-
rant expression of the FHITgene may play a critical role in the gener-
ation of squamous cell carcinoma arising from the uterine cervix.
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